Skip to main content

Novavax tumbles 31% as waning COVID-19 vaccine demand hits revenue forecast

Novavax fell 31% Tuesday amid falling demand for the COVID-19 shot from low and middle-income nations, which caused the company to cut its annual expectations in half.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.